Hormonal
Reallocating 30 minutes per day of sedentary time to sleep duration yields beneficial associations with insulin, HOMA-S, and HOMA-β, suggesting that extending sleep can improve metabolic health markers similarly to physical activity, though with a smaller magnitude of effect on some lipids.
If you spend a lot of time sitting, try shifting 30 minutes of that sitting time into extra sleep. This can help lower insulin and improve how your body handles glucose, offering a metabolic benefit similar to, though smaller than, exercise.
Reallocating 30 minutes/day of SB to sleep (Web Figure 5) had beneficial associations with insulin (2.3% lower), HOMA-S (2.0% higher), and HOMA-β (1.7% lower), as well as with LDL cholesterol in long sleepers only (4.8% lower).
Why this rating
Large sample with objective activity measures, but sleep was self-reported, and cross-sectional design limits causality.
Source
Reallocating Time to Sleep, Sedentary Behaviors, or Active Behaviors: Associations With Cardiovascular Disease Risk Biomarkers, NHANES 2005–2006
Matthew P. Buman et al. · American Journal of Epidemiology · 2013
DOI 10.1093/aje/kwt292
More from this paper
- Reallocating 30 minutes per day of sedentary time to moderate-to-vigorous physical activity (MVPA) yields the most potent improvements in cardiovascular disease risk biomarkers, including significant reductions in waist circumference, triglycerides, and insulin, and increases in HDL cholesterol and insulin sensitivity.Good
- Reallocating 30 minutes per day of sedentary time to light-intensity physical activity (LIPA) yields beneficial but smaller improvements in triglycerides, insulin, and insulin sensitivity compared to MVPA.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →